Integrating MRI in prostate cancer screening pathways reduces the number of unnecessary biopsies and the overdiagnosis of insignificant cancers, while maintaining clinically significant prostate cancer detection as compared with PSA-only screening. https://ja.ma/3XslNEY
JAMA Oncology
Book and Periodical Publishing
Chicago, Illinois 34,666 followers
A member of the JAMA Network, which includes JAMA, 11 specialty journals, and JAMA Network Open.
About us
JAMA Oncology is published online weekly, every Thursday, and in 12 print/online issues a year. The journal receives more than 6.4 million annual article views and downloads. Without any author fees, all research articles are made free access online 12 months after publication on the website. In addition, the online version is freely available or nearly so to institutions in developing countries through the World Health Organization's HINARI program. JAMA Oncology is a member of the JAMA Network, a consortium of peer-reviewed, general medical and specialty publications. The journal’s acceptance rate is 13%. The median time to first decision is 2 days, and 50 days with review. The Journal Impact Factor is 28.4, one of the highest ranking among oncology journals. All articles are published online first. Mary L. (Nora) Disis, MD, Director of the UW Institute of Translational Health Science and the Center for Translational Medicine in Women's Health, is the editor in chief.
- Website
-
https://jamanetwork.com/journals/jamaoncology
External link for JAMA Oncology
- Industry
- Book and Periodical Publishing
- Company size
- 5,001-10,000 employees
- Headquarters
- Chicago, Illinois
- Founded
- 2015
- Specialties
- Oncology
Updates
-
This case series reports durable remissions in 2 patients with relapsed/refractory B-cell acute lymphoblastic leukemia treated with allogeneic bispecific CD19/CD22-targeting chimeric antigen receptor T cells. https://ja.ma/4exy4hp
Allogeneic CD19/CD22 CAR T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia
jamanetwork.com
-
Loss in skeletal muscle mass during systemic therapy for NSCLC is a marker of poor outcomes, especially in male patients, suggest results of this multicohort study. https://ja.ma/4eovl9Y
Body Composition in Advanced Non-Small Cell Lung Cancer Treated With Immunotherapy
jamanetwork.com
-
This Special Communication discusses case-referenced consensus and evidence-based guidelines to inform clinical practice in unresectable locally advanced NSCLC. https://ja.ma/4cNAoz6
-
In patients with node-positive breast cancer, axillary recurrence after omission of axillary lymph node dissection was rare with no difference by type of surgery (sentinel lymph node biopsy with dual-tracer mapping vs targeted axillary dissection). https://ja.ma/45SzVcA
-
In patients with resected stage II/III gallbladder cancers, both gemcitabine plus cisplatin, and capecitabine and capecitabine concurrent w/ chemoradiation, showed 1-yr disease-free survival rates beyond the prespecified trial criteria of greater than 77%. https://ja.ma/4cr8tFA
Adjuvant Chemotherapy and Chemoradiation in Gallbladder Cancer
jamanetwork.com
-
Surveillance of high-risk individuals for pancreatic ductal adenocarcinoma using EUS or MRI led to a higher proportion of stage I cancers (31% vs 10%), longer 5-yr survival rate (50% vs 9%), and lower pancreatic cancer–specific mortality rate (43% vs 86%). https://ja.ma/3zwJWQY
-
Most viewed in the last 7 days from JAMA Oncology: Does perioperative FOLFIRINOX improve survival in patients with resectable pancreatic ductal adenocarcinoma? https://ja.ma/3XIjUUT
-
New 18-gene high-grade prostate cancer test had higher diagnostic accuracy for high-grade prostate cancer relative to existing biomarker tests, finds diagnostic study. https://ja.ma/45Ahx8d
Development and Validation of an 18-Gene Urine Test for High-Grade Prostate Cancer
jamanetwork.com
-
Next Generation Trial: phase 2 prospective validating paired-cohort trial finds 18F-PSMA-1007 PET/CT correctly identified the final pathological T-stage in 45% of men undergoing robotic prostatectomy compared to 28% w/ multiparametric MRI. https://ja.ma/4bnm537